{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:01:22Z","timestamp":1791756082678,"version":"4.3.4"},"reference-count":36,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004017","name":"Japanese Association of Dialysis Physicians","doi-asserted-by":"publisher","award":["23065"],"award-info":[{"award-number":["23065"]}],"id":[{"id":"10.13039\/501100004017","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Kidney Foundation","award":["JKFB 11-54"],"award-info":[{"award-number":["JKFB 11-54"]}]},{"name":"Research and Study Program of Tokai University Educational System General Research","award":["JP25461257"],"award-info":[{"award-number":["JP25461257"]}]},{"name":"Roche Diagnostics K.K."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure, but its role in the pathogenesis of renal bone disease remains unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to explore the association of serum sclerostin with bone metabolism in patients undergoing hemodialysis, with a particular focus on parathyroid hormone (PTH)-dependent and PTH-independent pathways.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This cross-sectional and prospective cohort study included 654 patients undergoing hemodialysis at 10 facilities in Japan. We employed multivariable linear regression to explore whether sclerostin levels were associated with metacarpal bone mineral density (BMD), intact PTH, bone alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase-5b (TRACP-5b). We employed mediation analyses to explore whether and to what extent the association of PTH with bone turnover markers is mediated by sclerostin. We also compared sclerostin levels between patients with and without previous or incident fractures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median sclerostin level in hemodialysis patients was 3- to 4-fold higher than that in healthy individuals. Higher sclerostin levels were associated with higher metacarpal BMD and lower levels of intact PTH, BAP, and TRACP-5b. However, the relationships of sclerostin with bone turnover markers were substantially attenuated after adjustment for PTH. Mediation analysis suggested that the effects of PTH on bone turnover markers were mainly direct rather than mediated by sclerostin. Sclerostin levels were not associated with previous or incident fractures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings suggest that in patients undergoing dialysis, sclerostin has only a limited role in bone metabolism and may not mediate the effect of PTH on bone turnover.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab623","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:09:12Z","timestamp":1629716952000},"page":"e95-e105","source":"Crossref","is-referenced-by-count":16,"title":["Interrelationships Between Sclerostin, Secondary Hyperparathyroidism, and Bone Metabolism in Patients on Hemodialysis"],"prefix":"10.1210","volume":"107","author":[{"given":"Yosuke","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-4507","authenticated-orcid":false,"given":"Hirotaka","family":"Komaba","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 259-1193, Japan"},{"name":"The Institute of Medical Sciences, Tokai University, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Hamano","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisae","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Transplant Surgery, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-1872","authenticated-orcid":false,"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Transplant Surgery, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Diabetes, Tokai University Oiso Hospital, Oiso, 259-0198, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Jinken Clinic, Ebina, 243-0436, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hyodo","sequence":"additional","affiliation":[{"name":"Medical Corporation Kuratakai, Hiratsuka, 254-0018, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Hida","sequence":"additional","affiliation":[{"name":"Medical Corporation Kuratakai, Hiratsuka, 254-0018, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Suga","sequence":"additional","affiliation":[{"name":"Medical Corporation Showakai, Tokyo, 160-0023, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Kakuta","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University Hachioji Hospital, Hachioji, 192-0032, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-2339","authenticated-orcid":false,"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"issue":"1","key":"2021121823151841500_CIT0001","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int."},{"issue":"7","key":"2021121823151841500_CIT0002","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int."},{"issue":"3","key":"2021121823151841500_CIT0003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00774-012-0411-z","article-title":"Increased risk of hip fracture among Japanese hemodialysis patients","volume":"31","author":"Wakasugi","year":"2013","journal-title":"J Bone Miner Metab."},{"issue":"1","key":"2021121823151841500_CIT0004","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int."},{"issue":"53","key":"2021121823151841500_CIT0005","doi-asserted-by":"crossref","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","article-title":"Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways","volume":"285","author":"Krause","year":"2010","journal-title":"J Biol Chem."},{"issue":"5","key":"2021121823151841500_CIT0006","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2215\/CJN.07670712","article-title":"The relation between renal function and serum sclerostin in adult patients with CKD","volume":"8","author":"Pelletier","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"2021121823151841500_CIT0007","doi-asserted-by":"crossref","first-page":"E1854","DOI":"10.1210\/jc.2014-2042","article-title":"Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients","volume":"99","author":"Kanbay","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021121823151841500_CIT0008","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1210\/jc.2014-2372","article-title":"Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients","volume":"99","author":"Ishimura","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021121823151841500_CIT0009","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2215\/CJN.06550810","article-title":"Sclerostin and Dickkopf-1 in renal osteodystrophy","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"2021121823151841500_CIT0010","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2215\/CJN.09470913","article-title":"Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis","volume":"9","author":"Malluche","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"2021121823151841500_CIT0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone."},{"issue":"11","key":"2021121823151841500_CIT0012","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology."},{"issue":"4","key":"2021121823151841500_CIT0013","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.kint.2020.02.035","article-title":"Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis","volume":"98","author":"Nakagawa","year":"2020","journal-title":"Kidney Int."},{"issue":"5893","key":"2021121823151841500_CIT0014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"Br Med J."},{"issue":"7","key":"2021121823151841500_CIT0015","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1210\/jc.2011-0254","article-title":"Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays","volume":"96","author":"McNulty","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121823151841500_CIT0016","volume-title":"Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach","author":"Hayes","year":"2018","edition":"2nd"},{"issue":"1","key":"2021121823151841500_CIT0017","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ndt\/gfr270","article-title":"Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients","volume":"27","author":"Cejka","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"2021121823151841500_CIT0018","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000355781","article-title":"Sclerostin blood levels before and after kidney transplantation","volume":"39","author":"Bonani","year":"2014","journal-title":"Kidney Blood Press Res."},{"issue":"1","key":"2021121823151841500_CIT0019","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jc.2013-2786","article-title":"Renal elimination of sclerostin increases with declining kidney function","volume":"99","author":"Cejka","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021121823151841500_CIT0020","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.1630","article-title":"Repression of osteocyte Wnt\/\u03b2-catenin signaling is an early event in the progression of renal osteodystrophy","volume":"27","author":"Sabbagh","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2021121823151841500_CIT0021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021121823151841500_CIT0022","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2013the six-month effect of risedronate and teriparatide","volume":"23","author":"Polyzos","year":"2012","journal-title":"Osteoporos Int."},{"issue":"6","key":"2021121823151841500_CIT0023","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-3419","article-title":"Serum sclerostin and risk of hip fracture in older Caucasian women","volume":"97","author":"Arasu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121823151841500_CIT0024","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","article-title":"Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study","volume":"24","author":"Garnero","year":"2013","journal-title":"Osteoporos Int."},{"issue":"12","key":"2021121823151841500_CIT0025","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3390\/jcm8122027","article-title":"Clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease","volume":"8","author":"De Mar\u00e9","year":"2019","journal-title":"J Clin Med."},{"issue":"4","key":"2021121823151841500_CIT0026","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.kint.2016.06.019","article-title":"Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease","volume":"90","author":"Cejka","year":"2016","journal-title":"Kidney Int."},{"issue":"5","key":"2021121823151841500_CIT0027","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell."},{"issue":"10","key":"2021121823151841500_CIT0028","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"Plos One."},{"issue":"1","key":"2021121823151841500_CIT0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5414\/CN109333","article-title":"Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates","volume":"90","author":"J\u00f8rgensen","year":"2018","journal-title":"Clin Nephrol."},{"issue":"16","key":"2021121823151841500_CIT0030","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"15","key":"2021121823151841500_CIT0031","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2021121823151841500_CIT0032","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2021121823151841500_CIT0033","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/ndt\/13.9.2294","article-title":"Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients","volume":"13","author":"Coen","year":"1998","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"2021121823151841500_CIT0034","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1681\/ASN.2017050584","article-title":"Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy","volume":"29","author":"Salam","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"2021121823151841500_CIT0035","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem."},{"issue":"4","key":"2021121823151841500_CIT0036","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-011-1656-4","article-title":"Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered","volume":"23","author":"Moustafa","year":"2012","journal-title":"Osteoporos Int."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab623\/40348561\/dgab623.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e95\/41819498\/dgab623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e95\/41819498\/dgab623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:18:17Z","timestamp":1639869497000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/1\/e95\/6356460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,23]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab623","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,23]]}}}